Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
OTLK Outlook Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: OTLK
Price (delayed)
$1.68
Market cap
$56.39M
P/E Ratio
0.89
Dividend/share
N/A
EPS
$1.89
Enterprise value
$82.16M
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010/LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME
Highlights
The net income has soared by 145% from the previous quarter and by 113% YoY
The EPS has soared by 141% from the previous quarter and by 116% YoY
The quick ratio has soared by 150% since the previous quarter but it has dropped by 66% year-on-year
OTLK's debt is down by 26% year-on-year but it is up by 7% since the previous quarter
Key stats
What are the main financial stats of OTLK
Market
Valuations
Earnings
Shares outstanding
33.57M
Market cap
$56.39M
Enterprise value
$82.16M
Price to earnings (P/E)
0.89
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
3.89
EV/EBITDA
3.86
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$76.44M
Net income
$21.12M
EBIT
$21.14M
EBITDA
$21.26M
Free cash flow
-$64.05M
Per share
Balance sheet
Liquidity
EPS
$1.89
EPS diluted
-$0.91
Free cash flow per share
-$2.07
Book value per share
-$1.01
Revenue per share
$0
TBVPS
$0.62
Total assets
$19.08M
Total liabilities
$51.54M
Debt
$33.32M
Equity
-$32.46M
Working capital
-$7.02M
Debt to equity
-1.03
Current ratio
0.72
Quick ratio
0.3
Net debt/EBITDA
1.21
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
75.4%
Return on equity
N/A
Return on invested capital
414%
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OTLK stock price
How has the Outlook Therapeutics stock price performed over time
Intraday
-1.47%
1 week
-5.08%
1 month
5%
1 year
-77.98%
YTD
-11.11%
QTD
37.7%
Financial performance
How have Outlook Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$76.44M
Net income
$21.12M
Gross margin
N/A
Net margin
N/A
The net income has soared by 145% from the previous quarter and by 113% YoY
OTLK's operating income is down by 28% YoY but it is up by 8% QoQ
Price vs fundamentals
How does OTLK's price correlate with its fundamentals
Growth
What is Outlook Therapeutics's growth rate over time
Valuation
What is Outlook Therapeutics stock price valuation
P/E
0.89
P/B
N/A
P/S
N/A
EV/EBIT
3.89
EV/EBITDA
3.86
EV/Sales
N/A
The EPS has soared by 141% from the previous quarter and by 116% YoY
Outlook Therapeutics's equity has surged by 76% YoY and by 35% QoQ
Efficiency
How efficient is Outlook Therapeutics business performance
The company's return on assets has surged by 161% QoQ and by 119% YoY
OTLK's return on invested capital has surged by 107% since the previous quarter
Dividends
What is OTLK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OTLK.
Financial health
How did Outlook Therapeutics financials performed over time
OTLK's total assets is 63% smaller than its total liabilities
The quick ratio has soared by 150% since the previous quarter but it has dropped by 66% year-on-year
The current ratio has soared by 125% from the previous quarter but it has contracted by 33% YoY
Outlook Therapeutics's equity has surged by 76% YoY and by 35% QoQ
OTLK's debt to equity has dropped by 66% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.